Paper SA02

Regulating the future: Navigating the complexities of 3D Printing in the Pharmaceutical Industry.

Burger Lubbe, MMS Holdings, Bloemfontein, South Africa

ABSTRACT

The use of 3D printing in the pharmaceutical industry has the potential to revolutionize drug formulation and medical device manufacturing, but it is also subject to strict regulatory requirements. This paper will provide an overview of the current regulatory landscape surrounding 3D printing and the practical impacts on the data and the analysis thereof.

We will examine the regulatory frameworks and guidelines set forth by regulatory authorities such as the FDA and the EMA, as well as international standards organizations such as the International Organization for Standardization (ISO). Furthermore, we will discuss the challenges associated with implementing 3D printing technology in a regulated environment, including quality control, validation, and documentation requirements. In addition, we will explore the implications of 3D printing on how trial data is structured and analyzed.

Finally, we will examine the potential future developments related to 3D printing in the pharmaceutical industry.

INTRODUCTION

In the ever-evolving landscape of healthcare and technology, innovative breakthroughs hold the promise of reshaping patient-centered medicine. At the forefront of these transformative innovations stands 3D printing, a dynamic tool that has revolutionized medical device manufacturing and unlocked the potential of personalized healthcare. This paper embarks on an extensive exploration of 3D printing's indispensable role within the pharmaceutical industry, with a particular emphasis on its application in point-of-care settings.

In recent years, additive manufacturing processes have seized the spotlight, providing an alternative to traditional subtractive methods. However, this transition is not without its unique challenges and advantages. This paper aims to demystify the additive manufacturing journey, unraveling the complexities from the genesis of digital models through Computer-Aided Design (CAD) and 3D scanning to the tangible realization of 3D-printed objects.
Beyond the intricacies of the manufacturing process, this paper delves into the realm of clinical studies that illuminate 3D printing's current application in healthcare. It critically examines research that measures the efficacy of personalized 3D-printed medical devices against their non-personalized counterparts, offering invaluable insights into the potential advantages of patient-specific treatment approaches.

As healthcare facilities embrace this transformative technology, they are compelled to uphold rigorous standards of regulatory adherence and quality assurance, safeguarding the health and well-being of patients in the era of point-of-care 3D printing. A prime example of this evolution is the "Health Institute Exemption" outlined in the Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR). This exemption introduces rigorous requirements for health institutions engaged in point-of-care manufacturing, signifying a paradigm shift. This paper sheds light on proactive efforts by the FDA, fostering collaboration with hospitals and the medical device community. Furthermore, it offers insight into the European perspective, where regulations have taken on heightened stringency, demanding comprehensive compliance measures from healthcare institutions.

Moreover, this paper envisions the future trajectory of 3D printing in individualized medicine. It underscores the pivotal role that 3D printing is poised to play in this remarkable journey, where innovation knows no bounds.

TECHNICAL ASPECTS OF 3D PRINTING

3D printing, also known as additive manufacturing, is a revolutionary process that fabricates three-dimensional objects from digital models. This technology has garnered significant attention across various industries, including healthcare. In this section, we delve into the technical fundamentals of 3D printing and its applications in pharmaceuticals.



Figure 1: Production cycle of 3D Printing

OBTAINING A 3D MODEL

In the process of obtaining the 3D model for printing, two methods are commonly employed and often in conjunction. The first method is computer-aided design or more commonly known as CAD, which is the utilization of computers or workstations to assist in the creation, modification, analysis, or optimization of designs. CAD programs plays a pivotal role in enhancing designer productivity, improving design quality, and establishing a manufacturing database.

The next method is 3D Scanning, this is achieved with the use of a 3D scanner. A 3D scanner is a device that digitizes real-life objects, creating digital replicas. To generate digital anatomical models, processes like CT or MRI scanning are often employed. This data is instrumental in software-driven tissue structure generation. The collaborative efforts of engineers, biomedical illustrators, radiologists, and technicians are crucial in this process.



Figure 2: 3D model created SolidWorks.



Figure 3: 3D scanner in the process of scanning.

SLICING AND G-CODE

The next step in the production cycle is to convert the 3D model into a format that can be understood by the software operating the 3D printer. In the most basic form this is achieved by a slicing program. The 3D model is most often in the STL digital file format. This 3D model STL file contains geometric information of the model. This means a mesh made up of triangular faces that represents the model as seen in figure 2. Before slicing begins, the imported 3D model undergoes optimization. This optimization algorithm differs depending on the slicing software used, but in general the optimization algorithm analyzes and establishes relationships between triangular faces within the model. This optimization simplifies memorization, facilitating efficient slicing. Slicing involves segmenting the 3D model into 2D layers.

The model is sliced layer by layer, each with a specific Z-axis height or layer height, forming 2D planes along the X and Y axes. The 2D plane intersects with triangular faces, as seen in figure 2, of the 3D model, creating coordinates. In the final step, the slicer compiles the geometry information, and coordinates of this stack of 2D planes into G Code or geometric code. This compilation also considers a set of parameters entered by the printing technician as well as the technical specification of the 3D printer.

Some of the most common parameters included by the technician are printing speed, layer height, support creation and adhesion assistance, and some of the most common technical specifications of the 3D printer are nozzle size, printer dimensions and filament width. This G Code serves as instructions for the 3D printer, directing it to print the target model. As can be seen in figure 5, the model now has 2D layers, that if combined makes up the 3D model. Note, that supports was also created using the slicing algorithm and is visible in figure 5 as the blue layers. The supports are necessary as it would be impossible to print without a layer below the current layer, and support are the temporary structures that facilitate that.



Figure 4: 3D Model before slicing.



Figure 5: 3D Model after slicing and support creation.

The G-code comprehensively outlines how the printer should produce each layer, manage support structures (when necessary), specify colour or material usage (especially when dealing with multiple materials), and execute other critical instructions. While it's important to note that not all 3D printers function identically, the fundamental principles underpinning this process remain consistent across the board.

PRINTER PREPARATION

The third crucial step involves preparing the 3D printer for the printing process. It's important to note that the specifics of this preparation can vary significantly depending on the type of 3D printer in use. While we won't delve into exhaustive detail, it's essential to understand the key elements involved:

- Cleaning: Ensuring that the 3D printer is free from any residual material or debris from previous prints is essential to maintain print quality and prevent errors.
- Loading the Printing Materials: Depending on the 3D printer's technology, loading the appropriate printing material, whether it's filament, resin, or other materials, is a critical step. Ensuring the right material is loaded is vital for the desired output.
- Levelling and Calibrating the Printing Surface: Achieving a perfectly level and calibrated printing surface is essential to ensure that each layer adheres accurately and consistently during the printing process. This step directly impacts the precision of the final product.
- General Maintenance: Routine maintenance, such as checking for loose parts, lubricating moving components, and ensuring the printer's overall health, is essential to prevent breakdowns and maintain long-term reliability.

These steps collectively contribute to the 3D printer's optimal performance, ensuring consistent and high-quality output during the printing process.

PRINTING

The fourth step marks the commencement of the actual printing process a pivotal phase that demands close supervision to prevent manufacturing errors. During this stage, various potential issues must be carefully monitored, including but not limited to:

- Layer Shifting: Ensuring that each layer is precisely aligned with the preceding one to avoid structural deformities.
- Adhesion Issues: Monitoring the adherence of each layer to the printing bed to prevent detachment or warping.
- Material Malfunctions: Verifying that the printing material flows consistently and correctly, preventing material-related issues.
- Layer separation: Some materials shrink significantly as they cool, in the case of larger prints some areas of a print will cool before the rest of the print causing uneven shrinking that could result in layer separation.

It's worth noting that this phase can be time intensive. It's not uncommon for the printing process to reveal flaws in the model, the slicing, or even the initial printer preparation. In such cases, it may be necessary to restart the process from the point where the origin of the issue was identified to ensure a successful outcome.

POST PROCESSING

In the fifth step is the critical phase of post-processing, where meticulous attention to detail is essential. This phase involves several key activities, each contributing to the refinement of the final print:

- Support Removal: The removal of temporary support structures, if used during printing, is a delicate process to ensure a smooth and intact final product.
- Curing (As Required): In certain cases, the print may require curing to harden the material fully. This step depends on the specific printing material and its curing requirements.
- Cleaning: Thorough cleaning ensures the removal of any residual material or debris, leaving the print in its pristine form.
- Sanding and Polishing: To achieve the desired surface finish and remove imperfections, sanding and polishing may be necessary.
- Final Inspection: Post-processing allows for a comprehensive final inspection to identify and rectify any flaws or imperfections, ensuring the print meets the desired quality standards.

This meticulous post-processing phase is integral to the production of high-quality 3D prints and ensures that the final product aligns with the intended design and specifications. This is also where the quality control happens and Good Manufacturing Processes should be followed.

FINAL PRODUCT

In the culmination of this intricate process a 3D printed object emerges, created from a digital file utilizing the principles of additive manufacturing. It’s worth noting at this point that when a device or drug is approved by a regulatory agency the material and the intended use is part of the evaluation and can’t be deviated from.

Each step in this journey conceals a wealth of regulation and guidelines, particularly as we transition from the current manufacturing cycle of medical devices and drugs, conducted by established manufacturing companies, to point-of-care production.

While current regulations and guidelines are well-established for traditional manufacturing by established manufacturers regardless of the manufacturing process, challenges arise when drugs and devices are printed at the point of care. This shifting landscape calls for innovative regulatory frameworks that can adapt to these transformative technologies.

CLINICAL ADVANCEMENTS IN 3D-PRINTED MEDICAL DEVICES

The integration of 3D printing into healthcare extends beyond the theoretical. In this section two studies will be examined to highlight the role of 3D printing in personalized medicine and how it is already being applied in clinical studies and patient care.

TITLE

Lumbar Fusion With 3D-Printed Porous Titanium Interbody Cages - A Single-Blinded Randomized Controlled Trial Evaluating Nexxt Matrixx™ Versus PEEK Cages

DESCRIPTION

This single-blinded randomized controlled trial assessed radiographic and clinical outcomes in patients who underwent combined interbody/posterolateral lumbar fusion procedures. The study compared two types of interbody cages: the Nexxt Spine Nexxt Matrixx 3D-printed titanium cage and the Honour poly-ether-ether-ketone (PEEK) cage, both supplemented with pedicle screw instrumentation.

The study focused on evaluating the safety and efficacy of the Nexxt Matrixx System titanium implant, in combination with a pedicle screw system, for lumbar interbody fusion procedures. A representative PEEK cage, commonly used in such procedures, served as the control. Importantly, both types of cages were utilized with milled local autograft bone, eliminating the need for iliac crest autograft.

This single-center trial enrolled a total of 70 subjects, with 35 participants in each group. All participants were followed for a duration of 24 months post-surgery. Eligible subjects included those scheduled for combined interbody/posterolateral lumbar fusion surgery. During the trial, subjects were randomly assigned to receive either the Nexxt Spine Nexxt Matrixx 3D-printed titanium cage or the Honour™ PEEK cage, along with a pedicle screw system and milled local autograft bone. Randomization took into account subjects' smoking status.

KEY FEATURES

- Subjects were blinded to their group allocation throughout the study.
- Data collection occurred at multiple time points, including preoperative, intraoperative, and postoperative assessments at 3, 6, 12, and 24 months.
- Inclusion criteria required subjects to be over 18 years old, unresponsive to conservative care for at least six months, and mentally, psychosocially, and physically capable of complying with the study protocol and providing informed consent.

This clinical trial provided valuable insights into the comparative effectiveness and safety of 3D-printed titanium cages versus traditional PEEK cages in lumbar fusion procedures, potentially contributing to improved patient outcomes and surgical practices in the field of spine surgery. Below is some of the results of the study that would seem to indicate an improvement in patient care through the personalized approach.

RESULTS

The Interbody Fusion Grading Scale (BSF Scale) assesses fusion between the interbody cage and adjacent bone, utilizing a numerical scale ranging from 1 to 3. Higher scores on this scale are indicative of more favorable outcomes. The specific grade definitions within the BSF Scale are as follows:

- BSF-1 (Brantigan, Steffee, Fraser-Grade 1): Represents radiographical pseudarthrosis.
- BSF-2 (Brantigan, Steffee, Fraser-Grade 2): Signifies radiographical locked pseudarthrosis.
- BSF-3 (Brantigan, Steffee, Fraser-Grade 3): Corresponds to radiographical fusion, denoting the most optimal outcome.

The study considers a fusion to be successful if it achieves a Grade BSF-3 status at the 6-month evaluation point.

Arm	3D-Printed Titanium Cage	PEEK Cage
Participants Analyzed	24	26
Units Analyzed	34	40
BSF Grade 3	27 (79.4)	10 (25.0)
BSF Grade 2	6 (17.6)	24 (60.0)
BSF Grade 1	0 (0.0)	6 (15.0)
Cage Removed	1 (2.9)	0 (0.0)

Table 1: Key results of the primary outcome.

TITLE

Does the Use of a Customized Titanium Reconstruction Plate for Orbital Fractures Result in Better Orbital Volume and Outcome

DESCRIPTION

This clinical trial, titled "Does the Use of a Customized Titanium Reconstruction Plate for Orbital Fractures Result in Better Orbital Volume and Outcome," is a prospective randomized longitudinal study that investigates the use of customized titanium reconstruction plates for treating orbital fractures. Orbital fractures are complex and challenging to treat due to the intricate bone anatomy and the proximity of vital structures.

The study aims to achieve the following primary objectives:

- Generate patient-specific models to pre-adapt titanium mesh for use in unilateral orbital fractures.
- Accurately restore orbital volume to pre-injury levels.
- Prevent postoperative complications, including enophthalmos (posterior displacement of the eyeball) and diplopia (double vision).
- Decrease operative time, leading to reduced overall costs and improved healthcare value.

Arm 1: Experimental - Treatment Group Patients in this group undergo orbital reconstruction using pre-adjusted patient-specific orbital implants created with office-based 3-dimensional printers (OB3DP). These implants are designed to fit each patient's unique anatomical needs and are manually adjusted according to the printed model.
Arm 2: Active Comparator - Control Group Patients in this group undergo orbital reconstruction with non-patient-specific orbital implants, following the traditional approach, which involves adapting standard stock orbital plates intraoperatively to the fractured orbit.

This clinical trial endeavors to improve patient outcomes by employing personalized healthcare in the form of customized titanium reconstruction plates while comparing them to conventional methods using non-customized implants. The study is conducted over a two-year period.

RESULTS

The study employed OsiriX, a medical software tool, for assessing orbital volume. This evaluation aimed to compare the orbital volumes of the injured and uninjured (contralateral) orbits. OsiriX MD, known for its advanced processing capabilities, facilitated precise measurements of orbital volume. Additionally, the software utilized DICOM data obtained from immediate postoperative CT scans to support the evaluation process.

Arm	Patient-specific (Personalized)	Non-patient-specific (Non-Personalized)
Overall Number of Participants Analyzed	13	12
Uninjured Orbit *	23 (3.5)	22.8 (2.6)
Reconstructed Orbit*	23.5 (3.2)	28.6 (3.6)
*Mean (Standard Deviation) | Unit of Measure: Cm^3		

Table 2: Orbital volume results.

The study also calculated the operating time, which spanned from fracture exposure and identification to the final implant placement and fixation. This duration was meticulously recorded in minutes and subsequently compared between the two treatment groups. The measurement of operative time was standardized and carried out using a stopwatch to ensure accuracy and facilitate a meaningful comparison between the treatment groups.

Arm	Patient-specific (Personalized)	Non-patient-specific (Non-Personalized)
Overall Number of Participants Analyzed	13	12
Length of surgery*	32.6(13.7)	53.3(12.8)
Time interval from plate insertion to fixation*	15.8(14.4)	41.4(9.4)
* Mean (Standard Deviation) | Unit of Measure: minutes		

Table 3: Operating time results.

The evaluation of treatment charges took into account several factors, which were meticulously considered:

- Facility Operating Room Charges: This encompassed anesthesia time, calculated by multiplying surgical time by the facility rate of $33 per minute.
- Hardware Charges: This included the expenses related to plates and screws used during the procedures.
- Length of Stay Charges (LOS): The LOS charges were determined by multiplying LOS by the facility daily rate of $1,690 per day.
- Cost of 3D Printed Model: This was inclusive of the cost of the 3D printer and filaments, which amounted to $1.5.

All variables related to treatment charges were sourced from the Grady Memorial Hospital Financial Planning and Analysis center. A comprehensive analysis compared the total treatment charges, encompassing facility operating room charges, hardware charges, LOS, and the cost of the 3D printed model, between the two groups. This analysis followed a similar methodology to that employed in previous studies conducted by our group.

Arm	Patient-specific (Personalized)	Non-patient-specific (Non-Personalized)
Overall Number of Participants Analyzed	13	12
Cost of Operation Room	992.54(524.63)	1,757.25(422.64)
Time interval from plate insertion to fixation*	15.8(14.4)	41.4(9.4)
3D Cost*	80(0)	0(0)
Length of Stay, Cost*	1690(0)	1690(0)
Cost of plate and screws*	840(0)	840(0)
Total Cost*	3602.54(524.63)	4287.25(422.64)
*Mean (Standard Deviation) | Unit of Measure: US Dollars		

Table 4: Operating cost results.

OBSERVATIONS RELATED TO THE CURENT USE OF 3D PRINTING

In certain instances, the intricacies inherent in study designs and data management pose challenges in determining the most accurate study designs and analyses. The advent of personalization further compounds this complexity within an already nonstandard approach.

While regulatory and automation trends lean towards standardization, the landscape of innovation pushes in an opposing direction, emphasizing individualized healthcare.

Moreover, as innovation progresses, a shift away from general medicine, characterized by one-size-fits-all approaches, is evident. Instead, a transition towards personalized medicine, incorporating gene-specific treatments, is underway. This transition extends even further towards the realm of individualized medicine, where implants, and potentially drugs or organs, are tailored for each patient. This evolving landscape necessitates a production method capable of meeting the demands of reduced-scale manufacturing. Notably, 3D printing has emerged as a promising solution.

Ensuring result consistency requires consideration of the manufacturing locations of medical devices. Similar to laboratory results, which are accompanied by specified ranges, device data should incorporate tolerances based on the production location and equipment employed for 3D printed interventions. In this context, just as laboratory equipment requires calibration, 3D printers should also undergo calibration to mitigate potential data discrepancies.

Furthermore, the shift towards individualized treatment raises questions about the applicability of traditional statistical approaches, primarily designed for large sample sizes. Analyzing an individual patient statistically presents unique challenges, warranting a more specialized exploration in statistical methodologies by those with expertise in the field.

CURRENT GUIDANCE AND REGULATION

This section discusses the current state of guidance in the United States and European Union, the exclusion of other regulatory agencies does not indicate a lack of guidance available. In this discussion utilizes the framework and guidance of the International Standards Organization (ISO) for standardizing terminology.

3D PRINTING IN POINT OF CARE FACILITIES

3D printing plays a dual role, serving as both an enabler of personalized medicine and a manufacturing method. In 2015, a significant milestone was reached when a drug for epilepsy gained approval, harnessing 3D printing's unique capabilities to craft intricate geometries beyond traditional manufacturing methods.

Key Points to Ponder

Before embarking on the integration of 3D printing for medical device manufacturing at point-of-care facilities, several vital considerations emerge:

- Certified Software: Prioritize access to certified medical device software for slicing and design, ensuring alignment with regulatory standards.
- Qualified Personnel: Employ experts for tasks involving segmentation, design, 3D printing, and post-processing. Specialized expertise is crucial in handling these intricate and time-consuming tasks.
- Varied Printer Range: Acknowledge the significant variation in cost and functionality among 3D printers. Opt for devices that align with the facility's diverse utilization cases.
- Material Selection and Storage: Exercise caution in material selection while strictly adhering to storage guidelines. This fosters a safe working environment and upholds the production of high-quality medical devices.
- Regulatory Compliance: Above all, uphold unwavering adherence to pertinent medical device regulations, prioritizing robust quality assurance processes as the bedrock of secure and effective medical device manufacturing.

These are just a few of the crucial considerations, as the realm of good manufacturing practices should also be explored. Furthermore, it's essential to comprehend that any device intended for patient treatment necessitates exemption or approval from regulatory agencies. This marks the beginning, rather than the conclusion, of our regulatory journey.

GUIDANCE FROM THE FDA

The FDA, recognizing the escalating significance of point-of-care 3D printing in healthcare, has taken decisive strides to furnish guidance and elucidation. This proactive stance harmonizes with the swift integration of 3D printers within hospital settings.

The FDA's recent release, titled "3D Printing Medical Devices at the Point of Care," lays out a discussion paper that ventures into myriad options accessible to hospitals seeking to institute in-house 3D printing facilities.

Highlighted Pathways

- Medical Device Production System (MDPS): Hospitals can opt for an MDPS model, encompassing materials, software, and equipment for on-site medical device production. Regulatory compliance and liability would be borne by the MDPS manufacturer, while the hospital functions as the user.

- Manufacturer Partnership: Another avenue involves partnering with a traditional manufacturer to deliver point-of-care services directly within the hospital. Here, the manufacturer assumes full responsibility for the devices produced.
- Self-Manufacturing: Alternatively, hospitals may choose to act as traditional manufacturers themselves. This encompasses securing FDA clearances, conducting requisite testing, and overseeing quality control, mirroring the obligations of conventional medical device manufacturers.

These options underscore the FDA's unwavering dedication to nurturing healthcare innovation while upholding safety and regulatory adherence. The FDA's active engagement with hospitals and the medical device community elucidates its commitment to charting the dynamic course of point-of-care 3D printing.

GUIDANCE IN EU

The implementation of the Medical Device Regulation (MDR) in May 2021, with an update in January 2023, has ushered in a new era of heightened scrutiny for medical 3D printing in point-of-care settings. These regulations, often termed the "Health Institute Exemption," are meticulously delineated in Article 5(5) of the MDR.

Crucial Point-of-Care Requirements

- Quality Management System: Point-of-care facilities must establish a robust quality management system, extending its purview to encompass control over any subcontractors involved.
- Compliance with Safety and Performance Standards: Adherence to the General Safety and Performance Requirements, meticulously outlined in the MDR, is paramount. This pertains to the performance, design, and manufacturing facets of medical devices.
- Justification for Non-Equivalent Devices: Institutions engaging in point-of-care manufacturing must furnish a cogent rationale elucidating why equivalent market-available devices cannot fulfil the specific requirements.
- Stringent Documentation: Thorough documentation, comprising technical records of the device, performance evaluations, and a declaration of compliance, is mandatory. Such documentation should be readily accessible for review by the pertinent national authorities upon request.
- Vigilant Surveillance: The establishment of a comprehensive surveillance system is imperative. This system should vigilantly monitor the manufacturing process and device utilization.

Under the MDR's purview, hospitals now bear the responsibility of crafting robust processes and systems if they choose to partake in point-of-care manufacturing. This level of compliance aligns closely with the expectations from conventional manufacturers, with an unwavering emphasis on patient safety. Notably, the Medical Device Coordination Group, a direct adjunct to the MDR, has meticulously curated a guidance document elucidating the landscape of custom-made medical devices. This document serves as an invaluable resource, providing lucidity and insights for institutions navigating the intricate terrain of evolving regulations in point-of-care 3D printing.

CONCLUSION

Unveiling the Future of Pharmaceutical and Healthcare Transformation

In the intricate realm where healthcare and innovation converge, 3D printing emerges as a formidable catalyst for transformation. This journey embarked on an exploration of the profound impact of 3D printing within the pharmaceutical industry. From its pivotal role in ushering in personalized medicine to navigating the evolving regulatory landscape, it delved into a world of limitless possibilities.

3D Printing: A Beacon of Personalized Healthcare

As this journey comes to a close, it becomes evident that 3D printing transcends its status as a mere manufacturing method; it assumes the mantle of an enabler for personalized healthcare. Its strategic deployment at the point of care empowers healthcare institutions to craft tailor-made solutions, ultimately enhancing patient outcomes and redefining the patient experience.

The Responsibility of Innovation

In the spirit of innovation, it's imperative to recognize that with great strides come great responsibilities. While this presentation provided a snapshot of the current regulatory landscape of 3D printing at the point of care, it's vital to acknowledge that the terrain of regulation is ever-evolving. Healthcare facilities, in navigating this landscape, must do so with unwavering diligence and commitment. The "Health Institute Exemption" underscores the need for the establishment of robust processes and systems, with patient safety as the unwavering lodestar in the era of point-of-care 3D printing.

Gratitude and a Vision for the Future

Appreciation extends to each participant for accompanying on this expedition, unraveling the multifaceted dimensions of 3D printing's role in shaping the pharmaceutical and healthcare future. The choice to join this quest has illuminated the path forward—a path where technology, regulation, and healthcare expertise harmonize. As the boundaries of what's attainable continue to be pushed, the dedication to the well-being of the patients served must remain

steadfast. Together, we stride into a future where innovation knows no bounds.

Charting a Course Toward Individualized Medicine
Moreover, as innovation charts its course, we witness a remarkable shift from the era of generalized medicine—where one size fits all—to the epoch of personalized medicine, where treatments are tailored to an individual's genetic profile. In envisioning the future, there lies a realm where not only implants but potentially drugs and organs are meticulously crafted to meet the unique needs of each patient. As production scales continue to diminish, a compelling solution emerges—the boundless potential of 3D printing.

In closing, this journey represents but a single step on this transformative odyssey, where the convergence of technology, regulation, and healthcare promises a brighter, more personalized future for all.

REFERENCES

Amin, D. (2022, July 27). The Use of 3D Printing in Orbital Fractures. Retrieved from classic.clinicaltrials.gov: https://classic.clinicaltrials.gov/ct2/show/NCT03673865

Andrew Grossbach, O. S. (2023, June 15). Lumbar Fusion With Nexxt Spine 3D-Printed Titanium Interbody Cages. Retrieved from classic.clinicaltrials.gov: https://classic.clinicaltrials.gov/ct2/show/study/NCT03647501

Faget, J. B. (2021, December 17). 3D Printing Medical Devices at the Point of Care — FDA Invites Feedback. Retrieved from Foley & Lardner LLP: https://www.foley.com/en/insights/publications/2021/12/3d-printing-medical-devices-point-of-care-fda#:~:text=FDA%20is%20considering%20how%20health%20care%20facilities%2C%20who,effective%3B%20Assuring%20the%20appropriate%20controls%20are%20place%3B%20and

FDA. (2021, October 12). U.S Food & Drug Administration. Retrieved from 3D Printing Medical Devices at the Point of Care: Discussion Paper: https://www.fda.gov/medical-devices/3d-printing-medical-devices/3d-printing-medical-devices-point-care-discussion-paper

FDA's Regulatory Framework for 3D Printing of Medical Devices at the Point of Care Needs More Clarity. (2022, July 27). Retrieved from Pew: https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2022/07/fdas-regulatory-framework-for-3d-printing-of-medical-devices-needs-more-clarity

Fotheringham, P. (2023, April 11). Medical 3D printing at the Point of Care: a regulatory comparison. Retrieved from insight surgery: https://www.insightsurgery.com/medical-3d-printing-at-the-point-of-care-a-regulatory-comparison/

Hoang D, Perrault D, Stevanovic M, Ghiassi A. Surgical applications of three-dimensional printing: a review of the current literature & how to get started. Ann Transl Med. 2016 Dec;4(23):456. doi: 10.21037/atm.2016.12.18. PMID: 28090512; PMCID: PMC5220021.

Medical Device Coordination Group. (2023, January). Retrieved from Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746: https://health.ec.europa.eu/system/files/2023-01/mdcg_2023-1_en.pdf

ACKNOWLEDGMENTS

I would like to express thanks to my company MMS Holdings for the time and resources that was made available to me, as well as my colleagues Faheeza Rangunwala and Pieter Cloete, and my wife Megan Carnell who supported and advised me through the process.

RECOMMENDED READING

Discussion Paper: 3D Printing Medical Devices at the Point of Care

Guidance on the health institution exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746

Government response to consultation on proposals to support the regulation of medicines manufactured at the Point of Care

Information technology — 3D printing and scanning — Framework for an Additive Manufacturing Service Platform (AMSP)

CONTACT INFORMATION

Your comments and questions are valued and encouraged. Contact the author at:

Burger Lubbe
MMS Holdings
6880 Commerce Blvd
Canton / MI 48187
Email: blubbe@mmsholdings.com
Web: www.mmsholdings.com